Skip to main navigation Skip to search Skip to main content

More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia

  • Y. O. Huh
  • , I. Jilani
  • , E. Estey
  • , F. Giles
  • , H. Kantarjian
  • , E. Freireich
  • , M. Albitar
  • The University of Texas Health Science Center at Houston

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

26 Citations (Scopus)

Abstract

Refractory anemia with excess blasts in transformation (RAEB-T) is a subgroup of myelodysplastic syndrome (MDS) in which the bone marrow blast count ranges from 20% to 30%. The recently proposed World Health Organization Classification of Hematologic Malignancies eliminated this category from MDS by lowering the blast count cutoff for acute myeloid leukemia (AML) from 30% to 20%. However, MDS is distinguished from AML by a significant increase in apoptosis. To investigate the difference in apoptosis between RAEB-T, AML, and other categories of MDS, we prospectively analyzed fresh bone marrow samples using the Annexin V and mitochondrial potential assays. There was a significantly higher level of apoptosis in RAEB-T than in AML according to both assays, while no significant differences between RAEB-T and other categories of MDS were noted. The data suggest that RAEB-T is more likely to be an advanced stage of MDS and biologically different from AML.

Original languageEnglish
Pages (from-to)2249-2252
Number of pages4
JournalLeukemia
Volume16
Issue number11
DOIs
Publication statusPublished - 1 Nov 2002
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Acute myelogenous leukemia
  • Apoptosis
  • Myelodysplastic syndrome
  • Refractory anemia with excess blasts in transformation

Fingerprint

Dive into the research topics of 'More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this